In late April, the Donald Trump administration announced plans to reschedule marijuana from a Schedule I to Schedule III substance.

On Saturday, Donald Trump signed an executive order aimed at accelerating clinical research into psychedelic drugs. The order focuses on expanding federal funding, reducing bureaucratic barriers, and speeding up regulatory timelines. The move signals a notable shift in U.S. federal posture toward psychedelics—distinct from ongoing developments at the state level—and arguably represents one of the most significant federal actions on psychedelic research and access to date.

A new meta-analysis challenges the narrative that psychedelic therapy outperforms antidepressants, showing comparable effectiveness when trials are evaluated under similar conditions.